Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 902 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 902 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84. Following the sale, the senior vice president now directly owns 3,524 shares of the company’s stock, valued at $168,870.08. This represents a 20.38 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.
• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ:MIRM opened at $48.54 on Wednesday. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock’s fifty day simple moving average is $43.90 and its two-hundred day simple moving average is $41.68. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $49.58. The stock has a market cap of $2.33 billion, a PE ratio of -24.03 and a beta of 0.98.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. During the same period last year, the business earned ($0.57) EPS. The business’s revenue was up 89.4% on a year-over-year basis. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MIRM. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Citigroup raised their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $57.10.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the period. Amalgamated Bank raised its stake in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock worth $46,000 after purchasing an additional 513 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after purchasing an additional 1,003 shares during the period. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth $69,000. Finally, Secure Asset Management LLC raised its stake in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock worth $1,651,000 after purchasing an additional 3,406 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.